Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Development of eptifibatide.

R M Scarborough1

  • 1COR Therapeutics, Inc, San Francisco, CA 94080, USA.

American Heart Journal
|November 30, 1999
PubMed
Summary
This summary is machine-generated.

Eptifibatide, a novel glycoprotein IIb/IIIa inhibitor, effectively reduces coronary events in acute coronary syndromes. This antithrombotic therapy shows significant benefits without increasing bleeding risk.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery of transition state factor Xa inhibitors as potential anticoagulant agents.

Current topics in medicinal chemistry·2002
Same author

Design, synthesis, and SAR of amino acid derivatives as factor Xa inhibitors.

Bioorganic & medicinal chemistry letters·2001
Same author

Design and synthesis of glycolic and mandelic acid derivatives as factor Xa inhibitors.

Bioorganic & medicinal chemistry letters·2001
Same author

Novel tricyclic benzothiazolo[2,3-c]thiadiazine antagonists of the platelet ADP receptor (P2Y(12)).

Bioorganic & medicinal chemistry letters·2001
Same author

Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 1: design of potent and specific 3,9-diazaspiro[5.5]undecanes.

Bioorganic & medicinal chemistry letters·2001
Same author

Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 2: design of potent antagonists containing the 3-azaspiro[5.5]undecanes.

Bioorganic & medicinal chemistry letters·2001
Same journal

Stratified Medicine with Eplerenone for Myocardial Infarction or Injury and No obstructive Coronary Arteries: A Registry-Based Basket Trial.

American heart journal·2026
Same journal

Revised Lipid-Lowering Therapy Guidelines in a Nationally Representative Sample.

American heart journal·2026
Same journal

Cardiometabolic Health of Low- and Higher-Income Adults in the United States, 2009-2023.

American heart journal·2026
Same journal

Moving Beyond Technical Capability to Regulatory Integration for Digital Health Technology Devices-Brief Communication from the Cardiovascular Sciences Research Consortium.

American heart journal·2026
Same journal

THE SOCIETY OF CRITICAL CARE CARDIOLOGY - RATIONALE, BLUEPRINT, AND LESSONS LEARNED IN THE CREATION OF A NEW MULTIDISCIPLINARY PROFESSIONAL ORGANIZATION.

American heart journal·2026
Same journal

DOAC Score Among Patients Receiving Vitamin K Antagonists.

American heart journal·2026
See all related articles

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Thrombosis Research

Background:

  • Acute coronary syndromes are primarily caused by thrombus formation, a process involving platelet aggregation.
  • Platelet aggregation is mediated by fibrinogen binding to the glycoprotein (GP) IIb/IIIa receptor.
  • Abciximab, an early GP IIb/IIIa inhibitor, demonstrated clinical effectiveness but had limitations, driving the development of new agents.

Purpose of the Study:

  • To evaluate the efficacy and safety of eptifibatide, a novel GP IIb/IIIa inhibitor, in patients with acute coronary syndromes.
  • To assess eptifibatide's role as an antithrombotic therapy in managing cardiovascular events.

Main Methods:

  • Eptifibatide, a cyclic heptapeptide, was developed by mimicking the GP IIb/IIIa inhibitor barbourin.

Related Experiment Videos

  • The study involved large-scale clinical trials, including the IMPACT II and PURSUIT phase III trials.
  • Patient populations ranged from low- to high-risk for acute coronary syndromes.

    • Main Results:

    • Eptifibatide demonstrated high specificity and affinity for the GP IIb/IIIa receptor.
    • It exhibits a rapid onset of antiplatelet action and rapid reversibility.
    • Clinical trials showed a significant reduction in coronary events across various patient risk levels.

    Conclusions:

    • Eptifibatide significantly reduces coronary events in patients with acute coronary syndromes.
    • The therapy was found to be safe, without a significant increase in bleeding complications.
    • Eptifibatide represents a valuable addition to existing antithrombotic treatment options.